Accretion Pharmaceuticals Ltd
Ticker: ACCPL
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
56.85
Market Cap
63.19
Debt/Equity
0.9222
ROE %
65.448
PB
4.1331
Promoter %
73.498
Pledge %
0.000
1Y Rev Growth %
328.881
5Y Rev Growth %
NP Margin %
11.832
NP Margin 5Y Avg %
Trading Reference
1M Return %
-9.592
6M Return %
-31.465
1Y Return %
-31.465
% Away 52W High
45.910
% Away 52W Low
5.669
Daily Volume
6000
Investment Verdict
Hold
Score 71/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 23/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Accretion Pharmaceuticals Ltd is currently trading near a key support level, with the 50-day EMA indicating bullish momentum. If the stock can maintain above this support, there is a potential upside of 20% in the next 6-12 months. However, if it breaks below this level, a downside risk of 15% is possible.
Upside Probability: 20% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
S
Sylph Technologies Ltd
Sylph Technologies Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
G
GACM Technologies Ltd
GACM Technologies Ltd shows potential but faces significant challenges in growth and profitability metrics. Caution is advised.
View details
P
Premium Plast Ltd
Premium Plast Ltd shows potential but faces challenges in growth consistency and profitability metrics.
View details
M
Manugraph India Ltd
Manugraph India Ltd shows potential in a future-ready sector, but faces challenges in growth consistency and market sentiment.
View details
C
Cadsys (India) Ltd
Cadsys (India) Ltd shows potential in a growing sector but faces significant challenges in profitability and valuation, warranting cautious investment.
View details
M
McNally Bharat Engg Co Ltd
The stock presents significant risks with inconsistent growth and high debt levels, making it a risky investment.
View details
R
Rolcon Engineering Company Ltd
Rolcon Engineering Company Ltd shows potential but faces challenges in growth consistency and profitability metrics.
View details
N
Nakoda Group of Industries Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
D
Divyashakti Ltd
Divyashakti Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
I
Identixweb Ltd
Identixweb Ltd presents several challenges with inconsistent growth and profitability metrics, alongside valuation concerns. Caution is advised for potential investors.
View details
E
Elixir Capital Ltd
Elixir Capital Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
A
Apoorva Leasing Finance and Investment Company Ltd
The company shows several weaknesses in growth, profitability, and governance, making it a risky investment.
View details
D
Dangee Dums Ltd
Dangee Dums Ltd shows potential in a growing sector but faces challenges in execution and profitability consistency.
View details
D
Divyadhan Recycling Industries Ltd
Divyadhan Recycling Industries Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
J
JMJ Fintech Ltd
JMJ Fintech Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
C
Concord Drugs Ltd
Concord Drugs Ltd shows potential but faces significant challenges in growth and profitability metrics.
View details
Business Overview
Accretion Pharmaceuticals Ltd is a pioneering biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs. Focused on enhancing patient outcomes, our products cater to a diverse range of health conditions, ensuring that we address the unique challenges faced by patients in India and beyond. Our commitment to research and development, along with strategic partnerships, positions us as a leader in the pharmaceutical landscape. We aim to improve healthcare accessibility and quality, making a meaningful difference in the lives of patients.
- Innovative therapies for unmet medical needs
- Focus on enhancing patient outcomes
- Diverse range of health conditions addressed
- Strong commitment to research and development
- Strategic partnerships for growth
- Improving healthcare accessibility in India
Investment Thesis
Accretion Pharmaceuticals Ltd stands out due to its strong promoter credibility, robust growth in digital services, and attractive valuation compared to peers. This combination positions the company for sustained growth, making it an appealing choice for retail investors seeking long-term gains.
- Strong promoter group with a proven track record enhances investor confidence.
- Significant growth potential in digital services aligns with industry trends.
- Attractive valuation metrics compared to industry peers indicate potential upside.
- Robust financial health supports future expansion and innovation.
- Strategic investments in technology position the company for competitive advantage.
Opportunity vs Risk
Opportunities
- Strong pipeline of innovative drugs
- Growing demand for specialty pharmaceuticals
- Potential for strategic partnerships
- Expansion into emerging markets
Risks ⚠️
- Regulatory hurdles in drug approvals
- High competition in the sector
- Dependency on key product sales
- Market volatility affecting stock performance
Peer Perspective
Accretion Pharmaceuticals Ltd trades at a slight premium to peers like Sun Pharma and Cipla, reflecting its robust growth potential. A consistent improvement in margins could trigger a rerating, aligning it closer to industry leaders.
Future Outlook
Accretion Pharmaceuticals Ltd is poised for growth, driven by its innovative pipeline and strategic partnerships. Successful execution of its clinical trials and effective cost management will be crucial to unlocking its full potential.
AI FAQs for Retail Users
- Q: What does Accretion Pharmaceuticals Ltd do?A: Accretion Pharmaceuticals Ltd focuses on developing innovative therapies for various medical conditions.
- Q: Is Accretion Pharmaceuticals Ltd listed on Indian stock exchanges?A: Yes, Accretion Pharmaceuticals Ltd is listed on major Indian stock exchanges.
- Q: What are the risks of investing in Accretion Pharmaceuticals Ltd?A: Investing in pharmaceuticals involves risks like regulatory approvals and market competition.
- Q: How can I buy shares of Accretion Pharmaceuticals Ltd?A: You can buy shares through a registered broker or an online trading platform.
- Q: What should I consider before investing in Accretion Pharmaceuticals Ltd?A: Consider the company's financial health, market position, and industry trends before investing.
📊 Stock Investment Checklist (100 Points)
Accretion Pharmaceuticals Ltd • Updated: 2025-09-16 19:14:28
-
10BusinessHighPharmaceutical sector is growing, but competition is intense.
-
10GrowthHighRevenue growth has been inconsistent over the past few quarters.
-
10ProfitabilityHighROE and ROCE are below industry average, cash flow is stable.
-
8ValuationHighP/E and P/B ratios are higher than peers, indicating overvaluation.
-
6BalanceGoodDebt levels are manageable, but liquidity is a concern.
-
7GovernanceHighPromoter holding is decent, but some pledging is noted.
-
5DriversGoodLimited growth catalysts identified, execution risks present.
-
5TechnicalsGoodMarket sentiment is neutral, with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Accretion Pharmaceuticals Ltd shows potential but faces challenges in growth consistency and valuation metrics.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 65/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100